

CeQur receives FDA approval for improved wearable insulin delivery device

03 October 2024 Adam Jeffs, Editor, SAE Media Group

The CeQur wearable insulin delivery device now provides 4 days of mealtime insulin, improving the ease of diabetes management



Credit: CeQur

CeQur, a South Carolina-based company developing wearable drug delivery solutions, has received FDA approval for its new patch. The company has improved upon its wearable insulin delivery patch, designed to replace mealtime insulin injections, by extending the wear time from three to four days.

CeQur announced the FDA approval for the improved patch in a [June 18 press release](#), highlighting that the extended wear time for the patch equates to over 1,000 fewer injections annually for patients.

IQVIA data from an analysis of over 26,000 patients suffering from type 2 diabetes suggests that many are not managing diabetes effectively. With only a little more than 21 percent achieving the ADA-recommended A1C goal of less than 7 percent. A1C is a test of the average amount of glucose in a patient's blood over the past three months. This data suggests that more effective and convenient methods for insulin delivery are needed, underscoring the value of the CeQur solution, which should improve dosing adherence.

According to Bradley Paddock, President and CEO at CeQur, the number of people turning to wearable insulin delivery solutions over the standard daily injections is growing:

“We are excited to share that there are now ~5000 people with diabetes using CeQur Simplicity for their mealtime insulin delivery. With the 4-day clearance, we hope to make it even easier for people with diabetes to take their mealtime insulin, he said.”

Now boasting the longest wearable time available for an insulin patch, the development could significantly improve quality of life for diabetes patients, making the task of managing the illness a more streamlined process. The advancement also signifies positive growth for the wearable drug delivery market as a whole.

The Wearable Injectors and Connected Devices conferences, both in the [UK](#) and [US](#), will feature a range of insightful talks from experts who will discuss the latest advancements in the field and share guidance on industry best practices.